Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACELYRIN, Inc.SLRN · Entity 79310 | CFO and CBO | August 31, 2024 | September 04, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | SVP, COO & CFO | May 15, 2022 | May 18, 2022 |
| Rezolute, Inc.RZLT · Entity 1990 | Director | November 19, 2025 | November 21, 2025 |
| Septerna, Inc.SEPN · Entity 2452 | Chief Financial Officer | February 06, 2026 | February 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACELYRIN, Inc.
Report date August 31, 2024 · Filed September 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2034-08-30 | Direct | 150,000 |
Reported balance
After 2024-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-31 · Grant · Acquired 150,000 · Balance 150,000 F1: 1/4 of the shares subject to the option vest on August 31, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4 of the shares subject to the option vest on August 31, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
NEKTAR THERAPEUTICS
Report date May 15, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 330,353 |
Reported balance
After 2022-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-15 · Grant · Acquired 28,750 · Balance 330,353 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied. F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 312,905 |
Reported balance
After 2022-05-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-05-16 · Sale · Disposed 17,448 · Balance 312,905 F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
F2: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied.
F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F5: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Rezolute, Inc.
Report date November 19, 2025 · Filed November 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 55,500 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Grant · Acquired 21,000 · Balance 55,500 F1: Represents grant of restricted stock units which fully vest on December 1, 2026. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2035-11-19 | Direct | 12,000 |
Reported balance
After 2025-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-19 · Grant · Acquired 12,000 · Balance 12,000 F2: The options fully vest on December 1, 2026. |
| Common SharesSEC Table I · non-derivative | IndirectThe Labrucherie Trust dated 9/1/2009 | 53,572 |
Reported balance
Holding disclosure · report date 2025-11-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 53,572 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units which fully vest on December 1, 2026.
F2: The options fully vest on December 1, 2026.
Septerna, Inc.
Report date February 06, 2026 · Filed February 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.41 · Expires 2036-02-05 | Direct | 125,000 |
Reported balance
After 2026-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 125,000 · Balance 125,000 F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 10, 2026 19:10 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001193125-26-045109 · ownership.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2036-02-05 F1 · derivative.exercise_date: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:36 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001279 · form4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 16:36 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001279 · form4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,500 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 19:06 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $11.70 | $0.00 |
DisclosureSEC source: 0000950170-25-106795 · ownership.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-08-06 F1 · derivative.exercise_date: 6/48th of the shares subject to such option shall vest and become exercisable on February 1, 2026 and the remaining shares subject to the option shall vest in 42 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 14:15 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000664 · form4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 14:15 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000664 · form4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| February 27, 2025 Filed Feb 27, 2025 18:51 UTC | Septerna, Inc. SEPN · Entity 2452 | PurchaseCommon Stock | 3,718 | $5.85 | $21,750.30 |
DisclosureSEC source: 0000950170-25-029330 · ownership.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 40,000 F2 · ownership.nature: The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 18:51 UTC | Septerna, Inc. SEPN · Entity 2452 | PurchaseCommon Stock | 6,282 | $5.59 | $35,116.38 |
DisclosureSEC source: 0000950170-25-029330 · ownership.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 36,282 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.50 to $5.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 21, 2025 Filed Feb 21, 2025 18:06 UTC | Septerna, Inc. SEPN · Entity 2452 | PurchaseCommon Stock | 5,000 | $5.85 | $29,250.00 |
DisclosureSEC source: 0000950170-25-025039 · ownership.xml · nonDerivative · entry 3 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 30,000 F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.77 to $5.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 18:06 UTC | Septerna, Inc. SEPN · Entity 2452 | PurchaseCommon Stock | 14,500 | $5.88 | $85,233.90 |
DisclosureSEC source: 0000950170-25-025039 · ownership.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 25,000 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.58 to $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 18:06 UTC | Septerna, Inc. SEPN · Entity 2452 | PurchaseCommon Stock | 10,500 | $5.51 | $57,813.00 |
DisclosureSEC source: 0000950170-25-025039 · ownership.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 10,500 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.48 to $5.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: The shares are held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 11:10 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000184 · form4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 11:10 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000184 · form4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| February 07, 2025 Filed Feb 7, 2025 16:37 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 222,000 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0000950170-25-016362 · ownership.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 222,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 6, 2026, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| August 31, 2024 Filed Sep 4, 2024 20:36 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001962918-24-000112 · wk-form4_1725493118.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-08-30 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on August 31, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 23, 2024 Filed May 24, 2024 18:59 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 184,042 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001962918-24-000065 · wk-form4_1716591539.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,042 Underlying: Common Stock · 184,042 shares Expires 2034-05-22 F1 · derivative.exercise_date: 33% of the shares subject to the option vest on December 15, 2024, 34% of the shares subject to the option vest on June 15, 2025, and the remaining 33% of the shares subject to the option vest on December 15, 2025, subject to the Reporting Person's continued service. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 12:08 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000079 · form4.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 18:26 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 855,513 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001962918-24-000004 · wk-form4_1705015575.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,513 Underlying: Common Stock · 855,513 shares Expires 2034-01-08 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 17:53 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 40,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-23-000034 · wk-form4_1696629224.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 40,763 F1 · kind: Represents a pro rata, in-kind distribution, and not a purchase or sale of securities, from Woodland Hills Partner LLC (the "LLC") to the Reporting Person, a limited partner of the LLC, without additional consideration. This distribution arises from the purchase of preferred stock by the Reporting Person as a limited partner in the LLC on the same pricing terms as the other participating investors in each round of financing. F2 · ownership.nature: Shares held directly by The Labrucherie Trust dated 9/1/2009, for which the Reporting Person serves as trustee. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 16:48 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 254,939 | $0.00 Strike: $26.94 | $0.00 |
DisclosureSEC source: 0001962918-23-000029 · wk-form4_1692650915.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,939 Underlying: Common Stock · 254,939 shares Expires 2033-08-16 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on August 17, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 17:43 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013409 · doc1.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Option shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| May 16, 2022 Filed May 18, 2022 01:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 17,448 | $3.95 | $68,919.60 |
DisclosureSEC source: 0001209191-22-029899 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,905 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 15, 2022 Filed May 18, 2022 01:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 28,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029899 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,353 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 04, 2022 Filed May 6, 2022 17:15 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Stock | 52,631 | $3.80 | $199,997.80 |
DisclosureSEC source: 0001567619-22-009699 · doc1.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,631 F1 · kind: The Reporting Person acquired these shares of common stock in connection with the Issuer's closing of registered direct public offering on May 4, 2022. Read SEC document |
| May 04, 2022 Filed May 9, 2022 16:28 UTC Amendment | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Stock | 52,631 | $3.80 | $199,997.80 |
DisclosureSEC source: 0001567619-22-009789 · doc1.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Labrucherie Trust dated 9/1/2009 Disclosed balance after: 53,572 F1 · kind: The Reporting Person acquired these shares of common stock in connection with the Issuer's closing of registered direct public offering on May 4, 2022. F2 · balance_after: Issuer effected a 50:1 reverse stock split on October 9, 2020. Reporting Person's indirect holdings following the split were 941 shares. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,579 | $10.95 | $82,990.05 |
DisclosureSEC source: 0001209191-22-011436 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,603 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.77 to $11.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:23 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 94,000 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-21-070690 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2029-12-15 F3 · derivative.exercise_date: This stock option vests over four years from the date of grant in equal monthly installments based on continued service. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:23 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 52,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070690 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,182 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,000 | $12.69 | $38,070.00 |
DisclosureSEC source: 0001209191-21-065592 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,682 F4 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 21,149 | $13.16 | $278,320.84 |
DisclosureSEC source: 0001209191-21-065592 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,682 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 40,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065220 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,831 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 12, 2021 Filed Oct 15, 2021 01:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 71,550 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-21-060509 · doc4.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,550 Underlying: Common Stock · 71,550 shares Expires 2027-12-11 F1 · security: These stock options were granted on December 12, 2019 under the Company's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Company determined that the performance-based vesting requirement for these stock options was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these stock options vested on the next monthly vesting date (October 12, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · derivative.exercise_date: These stock options vest on a monthly pro-rata basis over a period of four years from the grant date (December 12, 2019). Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 22:58 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,000 | $13.56 | $40,680.00 |
DisclosureSEC source: 0001209191-21-052384 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,231 F4 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 22:58 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,867 | $13.83 | $108,800.61 |
DisclosureSEC source: 0001209191-21-052384 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,231 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.69 to $14.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| June 14, 2021 Filed Jul 14, 2021 21:03 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013437 · doc1.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| May 17, 2021 Filed May 19, 2021 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,898 | $18.30 | $144,533.40 |
DisclosureSEC source: 0001209191-21-034184 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,098 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,977 | $22.37 | $178,445.49 |
DisclosureSEC source: 0001209191-21-012119 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,996 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.04 to $22.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 50,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · derivative · entry 13 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 50,000 | $19.81 | $990,500.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 9 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F7 · price: This transaction was executed in multiple trades at prices ranging from $19.50 to $20.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F1 · balance_after: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 50,000 | $8.80 | $440,000.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 8 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · derivative · entry 12 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · derivative · entry 11 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 50,000 | $19.61 | $980,500.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 7 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $19.30 to $19.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $8.80 | $220,000.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 6 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $8.80 | $220,000.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 5 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 50,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · derivative · entry 10 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 50,000 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,933 | $21.66 | $41,868.78 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 4 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,973 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $21.57 to $21.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,932 | $20.96 | $145,294.72 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,906 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.56 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 41,135 | $19.97 | $821,465.95 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,838 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.55 to $20.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 01:42 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 50,000 | $8.80 | $440,000.00 |
DisclosureSEC source: 0001209191-21-007942 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for certain options expiring on February 5, 2021. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.